Telix Pharmaceuticals (NASDAQ:TLX) Stock Rating Reaffirmed as “Outperform” by Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a research note issued on Wednesday, Benzinga reports. They presently have a $22.00 target price on the stock. Wedbush‘s target price suggests a potential upside of 119.34% from the company’s previous close.

A number of other brokerages have also issued reports on TLX. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Friday, September 25th. Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Finally, Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, September 21st. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.50.

Telix Pharmaceuticals Price Performance

TLX stock traded down $1.13 during mid-day trading on Wednesday, reaching $10.03. 874,436 shares of the company’s stock were exchanged, compared to its average volume of 236,494. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $13.11. The stock’s 50 day moving average is $11.49 and its 200 day moving average is $10.78.

Institutional Trading of Telix Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Lazard Asset Management LLC increased its position in shares of Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after purchasing an additional 39,400 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in Telix Pharmaceuticals in the 2nd quarter valued at $1,731,000. Private Advisor Group LLC lifted its holdings in Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares in the last quarter. XY Capital Ltd lifted its holdings in Telix Pharmaceuticals by 468.0% in the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after purchasing an additional 58,739 shares in the last quarter. Finally, WoodTrust Financial Corp acquired a new stake in Telix Pharmaceuticals during the 3rd quarter worth $186,000.

More Telix Pharmaceuticals News

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Q3 revenue increased 19% year over year. Telix reported continued commercial growth for the quarter ended September 30, 2026, supporting the company’s expanding radiopharmaceutical business. Telix Pharmaceuticals Q3 Revenue Rises 19%
• Positive Sentiment: Management reaffirmed its full-year 2026 outlook and highlighted ongoing progress across pipeline programs. Maintaining the forecast indicates that recent operating performance remains broadly on track. Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance And Advances Pipeline Programs
• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and assigned a $22 price target, signaling that the analyst sees substantial potential upside based on Telix’s commercial execution and pipeline.
• Neutral Sentiment: Telix also updated its third-quarter and full-year 2026 earnings guidance, while reports characterized the full-year outlook as reaffirmed rather than materially increased. Investors may therefore be looking for stronger upgrades to accelerate the stock’s recovery.
• Negative Sentiment: The market reaction has been weak despite the positive revenue result. Coverage describing the shares as “crashing” indicates possible profit-taking, disappointment that guidance was not raised, or concern that growth expectations were already reflected in the valuation. Telix shares crashing 8% today: What happened?

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.